View ValuationCalix 향후 성장Future 기준 점검 2/6Calix (는) 각각 연간 55.6% 및 22% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 63.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -47.6% 로 예상됩니다.핵심 정보55.6%이익 성장률63.39%EPS 성장률Chemicals 이익 성장27.9%매출 성장률22.0%향후 자기자본이익률-47.57%애널리스트 커버리지Low마지막 업데이트24 Feb 2026최근 향후 성장 업데이트Breakeven Date Change • Dec 24No longer forecast to breakevenThe 2 analysts covering Calix no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$3.50m in 2028. New consensus forecast suggests the company will make a loss of AU$19.2m in 2028.Breakeven Date Change • Aug 27Forecast to breakeven in 2028The 2 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 14% per year to 2027. The company is expected to make a profit of AU$3.60m in 2028. Average annual earnings growth of 51% is required to achieve expected profit on schedule.Breakeven Date Change • May 03Forecast to breakeven in 2022The 2 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$8.13m in 2022.Breakeven Date Change • Sep 18Forecast to breakeven in 2022The 3 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$845.6k in 2022. Earnings growth of 5.3% is required to achieve expected profit on schedule.모든 업데이트 보기Recent updates공시 • Feb 05Calix Limited to Report First Half, 2026 Results on Feb 24, 2026Calix Limited announced that they will report first half, 2026 results on Feb 24, 2026Breakeven Date Change • Dec 24No longer forecast to breakevenThe 2 analysts covering Calix no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$3.50m in 2028. New consensus forecast suggests the company will make a loss of AU$19.2m in 2028.공시 • Sep 22Calix Limited, Annual General Meeting, Nov 18, 2025Calix Limited, Annual General Meeting, Nov 18, 2025. Location: hybrid meeting, AustraliaBreakeven Date Change • Aug 27Forecast to breakeven in 2028The 2 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 14% per year to 2027. The company is expected to make a profit of AU$3.60m in 2028. Average annual earnings growth of 51% is required to achieve expected profit on schedule.Reported Earnings • Aug 26Full year 2025 earnings released: AU$0.096 loss per share (vs AU$0.14 loss in FY 2024)Full year 2025 results: AU$0.096 loss per share (improved from AU$0.14 loss in FY 2024). Revenue: AU$28.2m (up 17% from FY 2024). Net loss: AU$19.2m (loss narrowed 24% from FY 2024). Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 7.5% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings.공시 • Jul 29Calix Limited to Report Fiscal Year 2025 Results on Aug 26, 2025Calix Limited announced that they will report fiscal year 2025 results on Aug 26, 2025공시 • Dec 09Calix Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.Calix Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,666,667 Price\Range: AUD 0.75New Risk • Nov 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$148.5m (US$98.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$13m net loss in 3 years). Market cap is less than US$100m (AU$148.5m market cap, or US$98.3m).공시 • Sep 24Calix Limited, Annual General Meeting, Nov 22, 2024Calix Limited, Annual General Meeting, Nov 22, 2024.Reported Earnings • Aug 28Full year 2024 earnings released: AU$0.14 loss per share (vs AU$0.13 loss in FY 2023)Full year 2024 results: AU$0.14 loss per share (further deteriorated from AU$0.13 loss in FY 2023). Revenue: AU$24.2m (up 30% from FY 2023). Net loss: AU$25.3m (loss widened 9.0% from FY 2023). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings.공시 • Aug 20Calix Limited to Report Fiscal Year 2024 Results on Aug 27, 2024Calix Limited announced that they will report fiscal year 2024 results on Aug 27, 2024New Risk • Aug 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$150.7m (US$97.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$10m net loss in 2 years). Market cap is less than US$100m (AU$150.7m market cap, or US$97.3m).New Risk • Apr 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$41m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$14m net loss in 2 years). Share price has been volatile over the past 3 months (13% average weekly change).Recent Insider Transactions • Mar 14Non Executive Independent Director recently bought AU$87k worth of stockOn the 12th of March, Catriona Deans bought around 50k shares on-market at roughly AU$1.73 per share. This transaction increased Catriona's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.New Risk • Mar 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$41m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$41m free cash flow). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (AU$14m net loss in 2 years).Reported Earnings • Feb 25First half 2024 earnings released: AU$0.07 loss per share (vs AU$0.055 loss in 1H 2023)First half 2024 results: AU$0.07 loss per share (further deteriorated from AU$0.055 loss in 1H 2023). Revenue: AU$12.2m (up 41% from 1H 2023). Net loss: AU$12.6m (loss widened 37% from 1H 2023). Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.공시 • Feb 16Calix Limited to Report First Half, 2024 Results on Feb 23, 2024Calix Limited announced that they will report first half, 2024 results on Feb 23, 2024공시 • Dec 19Calix Limited Announces New Board Appointments, Effective 1 January 2024Calix Limited announced the appointments of Dr Sarah Ryan and Peter Dixon to the Calix board of directors as non-executive directors. Dr Ryan and Mr. Dixon's appointments will be effective from 1 January 2024. At the Calix 2022 Annual General Meeting, Calix Chair, Peter Turnbull noted the board's proactive approach to board succession and renewal to ensure the composition of the board is appropriate at all times to support the delivery of Calix's strategic goals. This process has been underway for some time and these latest appointments represent a major next step in Calix's board renewal. A further step is the expected retirement of Peter Turnbull prior to 30 June 2024, with Alison Deans set to become the new chair following Peter Turnbull's retirement. These changes will result in the Calix Board being comprised of four highly experienced non-executives and two executive directors, further enhancing the governance of the company. As a non-executive director and former senior operational executive, Dr Ryan brings extensive global engineering and commercial experience, encompassing private equity, investment management, energy sector operations, marketing, research, and team management. With a particular emphasis on innovation and technology enabled solutions, Dr Ryan has led and helped to build organizations across the energy, natural resources, and infrastructure sectors. Dr Ryan is currently a non-executive director of Viva Energy Group Limited (ASX:VEA), Aurizon Holdings Limited (ASX:AZJ), Transurban Group (ASX:TCL) and the Future Battery Industries Co- operative Research Centre. Until recently, Dr Ryan was a non-executive director of Oz Minerals Limited (ASX:OZL) and Woodside Energy Group Limited (ASX:WDS). Dr Ryan is also a Strategic Advisory Panel Member of the ARC Centre of Excellence for Green Electrochemical Transformation of Carbon Dioxide and Chair of the Energy Forum for the Australian Academy of Technological Sciences and Engineering.Dr Ryan holds a Bachelor of Science in Geology from the University of Melbourne, a Bachelor of Science (First Class Honours) in Geophysics from the University of Adelaide, and a PhD in Petroleum Geology and Geophysics from the University of Adelaide. Dr Ryan is also a Fellow of the Australian Academy of Technological Sciences and Engineering (ATSE), a Fellow of the Australian Institute of Energy, a Member of the Australian Institute of Company Directors, a Member of Women Corporate Directors, and a member of Chief Executive Women. With over 25 years of deep and diverse experience across the legal, investment banking and funds management sectors, Mr. Dixon brings expertise across corporate strategy, investment management, corporate advisory (including equity capital markets) and legal governance issues to the Calix board. Mr. Dixon is currently Chief Strategy Officer for HPX Group (which provides legal, compliance, governance and workplace services to a diverse range of clients across Australia and New Zealand), and is a non-executive director at Johns Lyng Group Limited. Mr. Dixon's investment banking and legal experience includes private legal practice experience at Mallesons Stephen Jacques in Sydney and Linklaters in London, as well as over nine years executive experience at MA Financial Group initially as an investment banker and ultimately as the group's General Counsel. Mr. Dixon also spent time earlier in his career at Macquarie Group Limited (ASX:MQG) in various roles across corporate strategy, investment management and corporate advisory. Peter's unique combination of skills and experience including in relation to complex corporate transactions and strategic options and execution will directly support Calix's strategic goals. Mr. Dixon holds a Bachelor of Commerce (Finance) and a Bachelor of Laws from the University of New South Wales. Mr. Dixon has previously been admitted to practice as a solicitor in New South Wales and in England and Wales.공시 • Oct 17Calix Limited, Annual General Meeting, Nov 16, 2023Calix Limited, Annual General Meeting, Nov 16, 2023, at 09:00 AUS Eastern Standard Time. Agenda: To consider remuneration report; to consider re election of Helen Fisher; to consider election of Alison Deans; to consider appointment of auditor; and to consider other matters.Reported Earnings • Aug 24Full year 2023 earnings released: AU$0.14 loss per share (vs AU$0.10 loss in FY 2022)Full year 2023 results: AU$0.14 loss per share (further deteriorated from AU$0.10 loss in FY 2022). Revenue: AU$18.6m (flat on FY 2022). Net loss: AU$23.2m (loss widened 42% from FY 2022). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 77% per year, which means it is well ahead of earnings.공시 • Aug 21Calix Limited to Report Fiscal Year 2023 Results on Aug 24, 2023Calix Limited announced that they will report fiscal year 2023 results on Aug 24, 2023Reported Earnings • Feb 21First half 2023 earnings released: AU$0.055 loss per share (vs AU$0.047 loss in 1H 2022)First half 2023 results: AU$0.055 loss per share (further deteriorated from AU$0.047 loss in 1H 2022). Revenue: AU$8.63m (down 12% from 1H 2022). Net loss: AU$9.17m (loss widened 23% from 1H 2022). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has increased by 88% per year, which means it is well ahead of earnings.공시 • Feb 13Calix Limited to Report First Half, 2023 Results on Feb 21, 2023Calix Limited announced that they will report first half, 2023 results on Feb 21, 2023공시 • Jan 30Calix Limited Receives Funding from the Australian Renewable Energy Agency and from Germany's Federal Ministry of Education and ResearchCalix Limited announced that the Solar Methanol Project (the Project), of which it is a consortium member, has been awarded funding to develop the production of sustainable fuels from captured process CO2 emissions. As announced by the Hon Chris Bowen MP, Minister for Climate Change and Energy on 27 January, the "HyGATE" Solar Methanol Project has been awarded AUD 19.48 million from the Australian Renewable Energy Agency (ARENA) and 13.2 million (AUD 20.19 million) from Germany's Federal Ministry of Education and Research (BMBF) to develop a world-first green methanol demonstration plant in Port Augusta, South Australia. The Solar Methanol Project Exporting green hydrogen produced in Australia to Germany offers the promise of leveraging Australia's abundant renewable energy resources to help the decarbonisation of German industry. Methanol is a versatile hydrogen derivative and has the potential to act as an effective green hydrogen carrier. Its clean and economical synthesis could help enable the decarbonisation of hard-to-abate transport sectors such as aviation and shipping. In addition to Calix, the Solar Methanol Project consortium includes Australian cleantech company Vast Solar and leading engineering and consultancy firm Fichtner, and is supported by the Australian Solar Thermal Institute. The Project aims to integrate several innovative low emission technologies to source renewable power and process heat, green hydrogen electrolysis, and, with Calix's Leilac technology, renewably powered electric calcination of limestone and the efficient capture of unavoidable process CO2 emissions. The Project intends to renewably power a 10MW electrolyser to produce green hydrogen, and a lime plant that produces CO2 as an unavoidable process emission. The clean energy, hydrogen and CO 2 will then be used to synthesise up to 7,500 tonnes per year of green methanol to be developed for use as a sustainable transport fuel. The Project aims to be a catalyst for a solar methanol industry in Australia, with the potential to significantly scale domestic green fuel use as well as potential exports to Germany and other global markets.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Helen Fisher was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 25Full year 2022 earnings released: AU$0.10 loss per share (vs AU$0.05 loss in FY 2021)Full year 2022 results: AU$0.10 loss per share (down from AU$0.05 loss in FY 2021). Revenue: AU$18.5m (down 3.9% from FY 2021). Net loss: AU$16.3m (loss widened 118% from FY 2021). Over the next year, revenue is forecast to grow 26%, compared to a 13% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 93% per year, which means it is well ahead of earnings.Breakeven Date Change • May 03Forecast to breakeven in 2022The 2 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$8.13m in 2022.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Helen Fisher was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 26First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: AU$0.047 loss per share (down from AU$0.017 loss in 1H 2021). Revenue: AU$9.82m (up 6.6% from 1H 2021). Net loss: AU$7.48m (loss widened 203% from 1H 2021). Revenue missed analyst estimates by 16%. Over the next year, revenue is forecast to grow 34%, compared to a 20% growth forecast for the industry in Australia.Board Change • Feb 25Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Helen Fisher was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Breakeven Date Change • Sep 18Forecast to breakeven in 2022The 3 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$845.6k in 2022. Earnings growth of 5.3% is required to achieve expected profit on schedule.Reported Earnings • Aug 26Full year 2021 earnings released: AU$0.061 loss per share (vs AU$0.05 loss in FY 2020)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2021 results: Revenue: AU$19.2m (up 37% from FY 2020). Net loss: AU$9.11m (loss widened 29% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 59% per year, which means it is well ahead of earnings.Analyst Estimate Surprise Post Earnings • Feb 27Revenue beats expectationsRevenue exceeded analyst estimates by 9.7%. Over the next year, revenue is forecast to grow 20%, compared to a 18% growth forecast for the Chemicals industry in Australia.Reported Earnings • Feb 26First half 2021 earnings released: AU$0.017 loss per share (vs AU$0.025 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: AU$9.21m (up 151% from 1H 2020). Net loss: AU$2.47m (loss narrowed 30% from 1H 2020).이익 및 매출 성장 예측CHIA:CXL - 애널리스트 향후 추정치 및 과거 재무 데이터 (AUD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수6/30/202854-12N/A-426/30/202746-13N/A-326/30/202637-34N/A-8212/31/202531-49-26-17N/A9/30/202530-34-33-23N/A6/30/202528-19-40-29N/A3/31/202527-22-36-22N/A12/31/202426-25-33-15N/A9/30/202425-25-33-14N/A6/30/202424-25-33-14N/A3/31/202423-26-37-18N/A12/31/202322-27-41-23N/A9/30/202320-25-35-20N/A6/30/202319-23-30-17N/A3/31/202318-21-23-12N/A12/31/202217-18-17-7N/A9/30/202218-17-15-5N/A6/30/202218-16-13-4N/A3/31/202219-14-16-8N/A12/31/202120-12-19-12N/A9/30/202120-10-17-10N/A6/30/202119-7-15-8N/A3/31/202119-7-9-1N/A12/31/202020-6-26N/A9/30/202017-718N/A6/30/202014-7410N/A3/31/202010-7-33N/A12/31/20195-6-9-3N/A9/30/20194-7N/A-1N/A6/30/20193-7N/A1N/A3/31/20194-7N/A2N/A12/31/20184-6N/A4N/A9/30/20184-5N/A3N/A6/30/20184-3N/A2N/A3/31/20184-3N/A1N/A12/31/20174-2N/A0N/A9/30/20174-2N/A-1N/A6/30/20174-2N/A-2N/A6/30/201614-2N/A2N/A6/30/20157-4N/A0N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: CXL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: CXL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: CXL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: CXL 의 수익(연간 22%)이 Australian 시장(연간 6.2%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: CXL 의 수익(연간 22%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: CXL는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YMaterials 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/23 08:35종가2026/05/22 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Calix Limited는 2명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Conor O’PreyCanaccord GenuityPhilip PepeShaw and Partners Limited
Breakeven Date Change • Dec 24No longer forecast to breakevenThe 2 analysts covering Calix no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$3.50m in 2028. New consensus forecast suggests the company will make a loss of AU$19.2m in 2028.
Breakeven Date Change • Aug 27Forecast to breakeven in 2028The 2 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 14% per year to 2027. The company is expected to make a profit of AU$3.60m in 2028. Average annual earnings growth of 51% is required to achieve expected profit on schedule.
Breakeven Date Change • May 03Forecast to breakeven in 2022The 2 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$8.13m in 2022.
Breakeven Date Change • Sep 18Forecast to breakeven in 2022The 3 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$845.6k in 2022. Earnings growth of 5.3% is required to achieve expected profit on schedule.
공시 • Feb 05Calix Limited to Report First Half, 2026 Results on Feb 24, 2026Calix Limited announced that they will report first half, 2026 results on Feb 24, 2026
Breakeven Date Change • Dec 24No longer forecast to breakevenThe 2 analysts covering Calix no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$3.50m in 2028. New consensus forecast suggests the company will make a loss of AU$19.2m in 2028.
공시 • Sep 22Calix Limited, Annual General Meeting, Nov 18, 2025Calix Limited, Annual General Meeting, Nov 18, 2025. Location: hybrid meeting, Australia
Breakeven Date Change • Aug 27Forecast to breakeven in 2028The 2 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 14% per year to 2027. The company is expected to make a profit of AU$3.60m in 2028. Average annual earnings growth of 51% is required to achieve expected profit on schedule.
Reported Earnings • Aug 26Full year 2025 earnings released: AU$0.096 loss per share (vs AU$0.14 loss in FY 2024)Full year 2025 results: AU$0.096 loss per share (improved from AU$0.14 loss in FY 2024). Revenue: AU$28.2m (up 17% from FY 2024). Net loss: AU$19.2m (loss narrowed 24% from FY 2024). Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 7.5% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings.
공시 • Jul 29Calix Limited to Report Fiscal Year 2025 Results on Aug 26, 2025Calix Limited announced that they will report fiscal year 2025 results on Aug 26, 2025
공시 • Dec 09Calix Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.Calix Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,666,667 Price\Range: AUD 0.75
New Risk • Nov 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$148.5m (US$98.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$13m net loss in 3 years). Market cap is less than US$100m (AU$148.5m market cap, or US$98.3m).
공시 • Sep 24Calix Limited, Annual General Meeting, Nov 22, 2024Calix Limited, Annual General Meeting, Nov 22, 2024.
Reported Earnings • Aug 28Full year 2024 earnings released: AU$0.14 loss per share (vs AU$0.13 loss in FY 2023)Full year 2024 results: AU$0.14 loss per share (further deteriorated from AU$0.13 loss in FY 2023). Revenue: AU$24.2m (up 30% from FY 2023). Net loss: AU$25.3m (loss widened 9.0% from FY 2023). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings.
공시 • Aug 20Calix Limited to Report Fiscal Year 2024 Results on Aug 27, 2024Calix Limited announced that they will report fiscal year 2024 results on Aug 27, 2024
New Risk • Aug 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$150.7m (US$97.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$10m net loss in 2 years). Market cap is less than US$100m (AU$150.7m market cap, or US$97.3m).
New Risk • Apr 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$41m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$14m net loss in 2 years). Share price has been volatile over the past 3 months (13% average weekly change).
Recent Insider Transactions • Mar 14Non Executive Independent Director recently bought AU$87k worth of stockOn the 12th of March, Catriona Deans bought around 50k shares on-market at roughly AU$1.73 per share. This transaction increased Catriona's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
New Risk • Mar 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$41m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$41m free cash flow). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (AU$14m net loss in 2 years).
Reported Earnings • Feb 25First half 2024 earnings released: AU$0.07 loss per share (vs AU$0.055 loss in 1H 2023)First half 2024 results: AU$0.07 loss per share (further deteriorated from AU$0.055 loss in 1H 2023). Revenue: AU$12.2m (up 41% from 1H 2023). Net loss: AU$12.6m (loss widened 37% from 1H 2023). Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
공시 • Feb 16Calix Limited to Report First Half, 2024 Results on Feb 23, 2024Calix Limited announced that they will report first half, 2024 results on Feb 23, 2024
공시 • Dec 19Calix Limited Announces New Board Appointments, Effective 1 January 2024Calix Limited announced the appointments of Dr Sarah Ryan and Peter Dixon to the Calix board of directors as non-executive directors. Dr Ryan and Mr. Dixon's appointments will be effective from 1 January 2024. At the Calix 2022 Annual General Meeting, Calix Chair, Peter Turnbull noted the board's proactive approach to board succession and renewal to ensure the composition of the board is appropriate at all times to support the delivery of Calix's strategic goals. This process has been underway for some time and these latest appointments represent a major next step in Calix's board renewal. A further step is the expected retirement of Peter Turnbull prior to 30 June 2024, with Alison Deans set to become the new chair following Peter Turnbull's retirement. These changes will result in the Calix Board being comprised of four highly experienced non-executives and two executive directors, further enhancing the governance of the company. As a non-executive director and former senior operational executive, Dr Ryan brings extensive global engineering and commercial experience, encompassing private equity, investment management, energy sector operations, marketing, research, and team management. With a particular emphasis on innovation and technology enabled solutions, Dr Ryan has led and helped to build organizations across the energy, natural resources, and infrastructure sectors. Dr Ryan is currently a non-executive director of Viva Energy Group Limited (ASX:VEA), Aurizon Holdings Limited (ASX:AZJ), Transurban Group (ASX:TCL) and the Future Battery Industries Co- operative Research Centre. Until recently, Dr Ryan was a non-executive director of Oz Minerals Limited (ASX:OZL) and Woodside Energy Group Limited (ASX:WDS). Dr Ryan is also a Strategic Advisory Panel Member of the ARC Centre of Excellence for Green Electrochemical Transformation of Carbon Dioxide and Chair of the Energy Forum for the Australian Academy of Technological Sciences and Engineering.Dr Ryan holds a Bachelor of Science in Geology from the University of Melbourne, a Bachelor of Science (First Class Honours) in Geophysics from the University of Adelaide, and a PhD in Petroleum Geology and Geophysics from the University of Adelaide. Dr Ryan is also a Fellow of the Australian Academy of Technological Sciences and Engineering (ATSE), a Fellow of the Australian Institute of Energy, a Member of the Australian Institute of Company Directors, a Member of Women Corporate Directors, and a member of Chief Executive Women. With over 25 years of deep and diverse experience across the legal, investment banking and funds management sectors, Mr. Dixon brings expertise across corporate strategy, investment management, corporate advisory (including equity capital markets) and legal governance issues to the Calix board. Mr. Dixon is currently Chief Strategy Officer for HPX Group (which provides legal, compliance, governance and workplace services to a diverse range of clients across Australia and New Zealand), and is a non-executive director at Johns Lyng Group Limited. Mr. Dixon's investment banking and legal experience includes private legal practice experience at Mallesons Stephen Jacques in Sydney and Linklaters in London, as well as over nine years executive experience at MA Financial Group initially as an investment banker and ultimately as the group's General Counsel. Mr. Dixon also spent time earlier in his career at Macquarie Group Limited (ASX:MQG) in various roles across corporate strategy, investment management and corporate advisory. Peter's unique combination of skills and experience including in relation to complex corporate transactions and strategic options and execution will directly support Calix's strategic goals. Mr. Dixon holds a Bachelor of Commerce (Finance) and a Bachelor of Laws from the University of New South Wales. Mr. Dixon has previously been admitted to practice as a solicitor in New South Wales and in England and Wales.
공시 • Oct 17Calix Limited, Annual General Meeting, Nov 16, 2023Calix Limited, Annual General Meeting, Nov 16, 2023, at 09:00 AUS Eastern Standard Time. Agenda: To consider remuneration report; to consider re election of Helen Fisher; to consider election of Alison Deans; to consider appointment of auditor; and to consider other matters.
Reported Earnings • Aug 24Full year 2023 earnings released: AU$0.14 loss per share (vs AU$0.10 loss in FY 2022)Full year 2023 results: AU$0.14 loss per share (further deteriorated from AU$0.10 loss in FY 2022). Revenue: AU$18.6m (flat on FY 2022). Net loss: AU$23.2m (loss widened 42% from FY 2022). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 77% per year, which means it is well ahead of earnings.
공시 • Aug 21Calix Limited to Report Fiscal Year 2023 Results on Aug 24, 2023Calix Limited announced that they will report fiscal year 2023 results on Aug 24, 2023
Reported Earnings • Feb 21First half 2023 earnings released: AU$0.055 loss per share (vs AU$0.047 loss in 1H 2022)First half 2023 results: AU$0.055 loss per share (further deteriorated from AU$0.047 loss in 1H 2022). Revenue: AU$8.63m (down 12% from 1H 2022). Net loss: AU$9.17m (loss widened 23% from 1H 2022). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has increased by 88% per year, which means it is well ahead of earnings.
공시 • Feb 13Calix Limited to Report First Half, 2023 Results on Feb 21, 2023Calix Limited announced that they will report first half, 2023 results on Feb 21, 2023
공시 • Jan 30Calix Limited Receives Funding from the Australian Renewable Energy Agency and from Germany's Federal Ministry of Education and ResearchCalix Limited announced that the Solar Methanol Project (the Project), of which it is a consortium member, has been awarded funding to develop the production of sustainable fuels from captured process CO2 emissions. As announced by the Hon Chris Bowen MP, Minister for Climate Change and Energy on 27 January, the "HyGATE" Solar Methanol Project has been awarded AUD 19.48 million from the Australian Renewable Energy Agency (ARENA) and 13.2 million (AUD 20.19 million) from Germany's Federal Ministry of Education and Research (BMBF) to develop a world-first green methanol demonstration plant in Port Augusta, South Australia. The Solar Methanol Project Exporting green hydrogen produced in Australia to Germany offers the promise of leveraging Australia's abundant renewable energy resources to help the decarbonisation of German industry. Methanol is a versatile hydrogen derivative and has the potential to act as an effective green hydrogen carrier. Its clean and economical synthesis could help enable the decarbonisation of hard-to-abate transport sectors such as aviation and shipping. In addition to Calix, the Solar Methanol Project consortium includes Australian cleantech company Vast Solar and leading engineering and consultancy firm Fichtner, and is supported by the Australian Solar Thermal Institute. The Project aims to integrate several innovative low emission technologies to source renewable power and process heat, green hydrogen electrolysis, and, with Calix's Leilac technology, renewably powered electric calcination of limestone and the efficient capture of unavoidable process CO2 emissions. The Project intends to renewably power a 10MW electrolyser to produce green hydrogen, and a lime plant that produces CO2 as an unavoidable process emission. The clean energy, hydrogen and CO 2 will then be used to synthesise up to 7,500 tonnes per year of green methanol to be developed for use as a sustainable transport fuel. The Project aims to be a catalyst for a solar methanol industry in Australia, with the potential to significantly scale domestic green fuel use as well as potential exports to Germany and other global markets.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Helen Fisher was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 25Full year 2022 earnings released: AU$0.10 loss per share (vs AU$0.05 loss in FY 2021)Full year 2022 results: AU$0.10 loss per share (down from AU$0.05 loss in FY 2021). Revenue: AU$18.5m (down 3.9% from FY 2021). Net loss: AU$16.3m (loss widened 118% from FY 2021). Over the next year, revenue is forecast to grow 26%, compared to a 13% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 93% per year, which means it is well ahead of earnings.
Breakeven Date Change • May 03Forecast to breakeven in 2022The 2 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$8.13m in 2022.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Helen Fisher was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 26First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: AU$0.047 loss per share (down from AU$0.017 loss in 1H 2021). Revenue: AU$9.82m (up 6.6% from 1H 2021). Net loss: AU$7.48m (loss widened 203% from 1H 2021). Revenue missed analyst estimates by 16%. Over the next year, revenue is forecast to grow 34%, compared to a 20% growth forecast for the industry in Australia.
Board Change • Feb 25Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Helen Fisher was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Breakeven Date Change • Sep 18Forecast to breakeven in 2022The 3 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$845.6k in 2022. Earnings growth of 5.3% is required to achieve expected profit on schedule.
Reported Earnings • Aug 26Full year 2021 earnings released: AU$0.061 loss per share (vs AU$0.05 loss in FY 2020)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2021 results: Revenue: AU$19.2m (up 37% from FY 2020). Net loss: AU$9.11m (loss widened 29% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 59% per year, which means it is well ahead of earnings.
Analyst Estimate Surprise Post Earnings • Feb 27Revenue beats expectationsRevenue exceeded analyst estimates by 9.7%. Over the next year, revenue is forecast to grow 20%, compared to a 18% growth forecast for the Chemicals industry in Australia.
Reported Earnings • Feb 26First half 2021 earnings released: AU$0.017 loss per share (vs AU$0.025 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: AU$9.21m (up 151% from 1H 2020). Net loss: AU$2.47m (loss narrowed 30% from 1H 2020).